Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

Bosutinib is an orally active, dual Src/Abl tyrosine kinase inhibitor for treatment of chronic myeloid leukemia (CML) following resistance/intolerance to prior therapy. Here, we report the data from the 2-year follow-up of a phase 1/2 open-label study evaluating the efficacy and safety of bosutinib...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Gambacorti-Passerini, Carlo, Brümmendorf, Tim H, Kim, Dong-Wook, Turkina, Anna G, Masszi, Tamas, Assouline, Sarit, Durrant, Simon, Kantarjian, Hagop M, Khoury, H Jean, Zaritskey, Andrey, Shen, Zhi-Xiang, Jin, Jie, Vellenga, Edo, Pasquini, Ricardo, Mathews, Vikram, Cervantes, Francisco, Besson, Nadine, Turnbull, Kathleen, Leip, Eric, Kelly, Virginia, Cortes, Jorge E
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Blackwell Publishing Ltd 2014
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4173127/
https://ncbi.nlm.nih.gov/pubmed/24711212
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23728
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia